JP2006526774A - テラヘルツ放射線を用いた定量分析の方法および装置 - Google Patents
テラヘルツ放射線を用いた定量分析の方法および装置 Download PDFInfo
- Publication number
- JP2006526774A JP2006526774A JP2006508373A JP2006508373A JP2006526774A JP 2006526774 A JP2006526774 A JP 2006526774A JP 2006508373 A JP2006508373 A JP 2006508373A JP 2006508373 A JP2006508373 A JP 2006508373A JP 2006526774 A JP2006526774 A JP 2006526774A
- Authority
- JP
- Japan
- Prior art keywords
- sample
- radiation
- thz
- excitation
- ghz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000005855 radiation Effects 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000004445 quantitative analysis Methods 0.000 title 1
- 230000005284 excitation Effects 0.000 claims abstract description 50
- 230000003595 spectral effect Effects 0.000 claims abstract description 32
- 230000001678 irradiating effect Effects 0.000 claims abstract description 8
- 238000001228 spectrum Methods 0.000 claims description 54
- 229940079593 drug Drugs 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 238000012795 verification Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002360 explosive Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 84
- 238000004458 analytical method Methods 0.000 description 23
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 18
- 229960001375 lactose Drugs 0.000 description 18
- 239000008101 lactose Substances 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 16
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- 229960001138 acetylsalicylic acid Drugs 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052594 sapphire Inorganic materials 0.000 description 4
- 239000010980 sapphire Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- -1 cefaclor dihydrate Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 229910017119 AlPO Inorganic materials 0.000 description 2
- WHXDLJOHWHFXJR-UHFFFAOYSA-N CC(=O)NC1=CC=C(O)C=C1.CC(=O)NC1=CC=C(O)C=C1 Chemical compound CC(=O)NC1=CC=C(O)C=C1.CC(=O)NC1=CC=C(O)C=C1 WHXDLJOHWHFXJR-UHFFFAOYSA-N 0.000 description 2
- 229910005543 GaSe Inorganic materials 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910013641 LiNbO 3 Inorganic materials 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229910007709 ZnTe Inorganic materials 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000009878 intermolecular interaction Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000005365 phosphate glass Substances 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052714 tellurium Inorganic materials 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- LBOUHDMYVURTMA-AATRIKPKSA-N (e)-3-(4-formylphenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(C=O)C=C1 LBOUHDMYVURTMA-AATRIKPKSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- SYOPRZWROBOKGX-ZJSXRUAMSA-N 2-(3,4-dichlorophenyl)-n-[(1r,2r)-5-methoxy-2-pyrrolidin-1-yl-1,2,3,4-tetrahydronaphthalen-1-yl]-n-methylacetamide Chemical compound N1([C@H]2[C@@H](C=3C=CC=C(C=3CC2)OC)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CCCC1 SYOPRZWROBOKGX-ZJSXRUAMSA-N 0.000 description 1
- JELDFLOBXROBFH-UHFFFAOYSA-N 2-[[4-[[2-(2h-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1OCC1=CC=CC=C1CC=1N=NNN=1 JELDFLOBXROBFH-UHFFFAOYSA-N 0.000 description 1
- PJKVJJYMWOCLIJ-UHFFFAOYSA-N 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-1h-quinazolin-4-one;hydron;dichloride Chemical compound Cl.Cl.CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 PJKVJJYMWOCLIJ-UHFFFAOYSA-N 0.000 description 1
- AXUZQJFHDNNPFG-LHAVAQOQSA-N 3-[(r)-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoic acid Chemical compound CN(C)C(=O)CCS[C@H](SCCC(O)=O)C1=CC=CC(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)=C1 AXUZQJFHDNNPFG-LHAVAQOQSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- NPXUFPFFHANGDL-UHFFFAOYSA-N 5-methyl-2-(2-nitroanilino)thiophene-3-carbonitrile Chemical compound S1C(C)=CC(C#N)=C1NC1=CC=CC=C1[N+]([O-])=O NPXUFPFFHANGDL-UHFFFAOYSA-N 0.000 description 1
- FRHCVEBCJCHBAI-UHFFFAOYSA-N 6-(2,2-dimethylpropyl)-2-oxo-1h-pyridine-3-carboxylic acid Chemical compound CC(C)(C)CC1=CC=C(C(O)=O)C(=O)N1 FRHCVEBCJCHBAI-UHFFFAOYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- ZVVCSBSDFGYRCB-UHFFFAOYSA-N 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-8-propyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound C1=CC(C(C)=O)=C(OC)C(CCC)=C1OCCCOC1=CC=C(CCC(O2)C(O)=O)C2=C1CCC ZVVCSBSDFGYRCB-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 239000005912 Lufenuron Substances 0.000 description 1
- AXUZQJFHDNNPFG-UXBLZVDNSA-N MK 571 Chemical compound CN(C)C(=O)CCSC(SCCC(O)=O)C1=CC=CC(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)=C1 AXUZQJFHDNNPFG-UXBLZVDNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WESWYMRNZNDGBX-YLCXCWDSSA-N Mefloquine hydrochloride Chemical compound Cl.C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 WESWYMRNZNDGBX-YLCXCWDSSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- FYDSPEWNDZOWPU-UHFFFAOYSA-N [3-nitrooxy-2,2-bis(nitrooxymethyl)propyl] nitrate;1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1.[O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O FYDSPEWNDZOWPU-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- LRAJHPGSGBRUJN-OMIVUECESA-N cefepime hydrochloride Chemical compound O.Cl.[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 LRAJHPGSGBRUJN-OMIVUECESA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- MEPNHSOMXMALDZ-UHFFFAOYSA-N delavirdine mesylate Chemical compound CS(O)(=O)=O.CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 MEPNHSOMXMALDZ-UHFFFAOYSA-N 0.000 description 1
- 229960000475 delavirdine mesylate Drugs 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- FXHKSTYWSZZOBF-NTEVMMBTSA-L disodium;(3s)-4-[2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethynyl-oxidophosphoryl]-3-hydroxybutanoate Chemical compound [Na+].[Na+].C12=CC=CC=C2C(C(C)C)=C(C#CP([O-])(=O)C[C@@H](O)CC([O-])=O)N1C1=CC=C(F)C=C1 FXHKSTYWSZZOBF-NTEVMMBTSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960001880 fosinopril sodium Drugs 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 229960000521 lufenuron Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960005329 mefloquine hydrochloride Drugs 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- FBFBRAFXKGRRHI-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyl-4-propan-2-yloxybenzamide Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(N)C=C1 FBFBRAFXKGRRHI-UHFFFAOYSA-N 0.000 description 1
- LQZGUJSFLJIJKA-UHFFFAOYSA-N n-(4-methyl-2-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC=C(C)C=C1[N+]([O-])=O LQZGUJSFLJIJKA-UHFFFAOYSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960005183 paroxetine hydrochloride Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- OUNSOXPSCMCFHX-UHFFFAOYSA-N pinadoline Chemical compound ClCCCCC(=O)NNC(=O)N1CC2=CC=CC=C2OC2=CC=C(Cl)C=C12 OUNSOXPSCMCFHX-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical compound [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 1
- 239000011028 pyrite Substances 0.000 description 1
- 229910052683 pyrite Inorganic materials 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- TVTJZMHAIQQZTL-WATAJHSMSA-M sodium;(2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-WATAJHSMSA-M 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229950001296 sulfaproxyline Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/3581—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared light; using Terahertz radiation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/3581—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared light; using Terahertz radiation
- G01N21/3586—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared light; using Terahertz radiation by Terahertz time domain spectroscopy [THz-TDS]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N22/00—Investigating or analysing materials by the use of microwaves or radio waves, i.e. electromagnetic waves with a wavelength of one millimetre or more
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/3554—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for determining moisture content
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
- G01N21/3563—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solids; Preparation of samples therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/12—Circuits of general importance; Signal processing
- G01N2201/129—Using chemometrical methods
Landscapes
- Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Electromagnetism (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Description
25GHzから100THzの範囲の複数の周波数を持つ放射線で試料を照射するステップと、
前記試料の周波数領域波形を得るため、前記試料から反射されたおよび/または前記試料を透過した放射線を検出するステップと、
分子間励起または他の非分子内励起によるスペクトル特性を含む、前記周波数領域波形の少なくとも一つの関心区画を定めるステップと、
前記区画から試料の成分濃度に関する値を得るステップと、
を有する方法が提供される。
密閉パッケージ内の気体量を定めるため、
25GHzから100THzの範囲の複数の周波数を持つ放射線で試料を照射するステップと、
前記試料の周波数領域波形を得るため、前記パッケージから反射されたおよび/または前記パッケージを透過した放射線を検出するステップと、
分子間励起または他の非分子内励起によるスペクトル特性を含む、前記周波数領域波形の少なくとも一つの関心区画を定めるステップと、
前記区画から前記パッケージ内の気体濃度に関する値を得るステップと、
が行われる、放射線の利用が得られる。
薬剤の成分量を定めるため、
25GHzから100THzの範囲の複数の周波数を持つ放射線で試料を照射するステップと、
前記試料の周波数領域波形を得るため、前記薬剤から反射されたおよび/または前記試料を透過した放射線を検出するステップと、
分子間励起または他の非分子内励起によるスペクトル特性を含む、前記周波数領域波形の少なくとも一つの関心区画を定めるステップと、
前記区画から薬剤の成分濃度に関する値を得るステップと、
が行われる、放射線の利用が得られる。
25GHzから100THzの範囲の複数の周波数を持つ放射線で試料を照射する光源と、
前記試料の周波数領域波形を得るため、前記試料から反射されたおよび/または前記試料を透過した放射線を検出する検出器と、
分子間励起または他の非分子内励起によるスペクトル特性を含む、前記周波数領域波形の少なくとも一つの関心区画を定める手段と、
前記区画から試料の成分濃度に関する値を得る手段と、を有する装置が提供される。
Claims (35)
- 試料を定量的に分析する方法であって、
25GHzから100THzの範囲の複数の周波数を持つ放射線で試料を照射するステップと、
前記試料の周波数領域波形を得るため、前記試料から反射されたおよび/または前記試料を透過した放射線を検出するステップと、
分子間励起または他の非分子内励起によるスペクトル特性を含む、前記周波数領域波形の少なくとも一つの関心区画を定めるステップと、
前記区画から試料の成分濃度に関する値を得るステップと、
を有する方法。 - 試料は、少なくとも2つの多形体のまたは擬似多形体の状態を形成することの可能な分子を含むことを特徴とする請求項1に記載の方法。
- 前記少なくとも2つの多形体のまたは擬似多形体の状態のスペクトル特性間に差異が存在するスペクトル領域が、関心区画として定められることを特徴とする請求項2に記載の方法。
- 前記試料は、異なる分子を含む2または3以上の成分を含むことを特徴とする請求項1に記載の方法。
- 試料は、活性成分と賦形剤とを含むことを特徴とする請求項1乃至4のいずれか一つに記載の方法。
- 試料は、分析されない成分を有し、関心区画は、分析されない前記成分から生じる顕著なスペクトル特性から離れた位置に選定されることを特徴とする前記請求項のいずれか一つに記載の方法。
- 試料は、固体成分を有することを特徴とする前記請求項のいずれか一つに記載の方法。
- 試料は、薬剤を有することを特徴とする前記請求項のいずれか一つに記載の方法。
- 試料は、爆発性物質を有することを特徴とする請求項1乃至7のいずれか一つに記載の方法。
- 試料は、気体状の少なくとも一つの成分を有することを特徴とする前記請求項のいずれか一つに記載の方法。
- 気体は、水蒸気であることを特徴とする請求項10に記載の方法。
- 関心区画は、気体に含まれる分子の回転励起によって生じる特性を含むスペクトル領域として選定されることを特徴とする請求項10または11のいずれかに記載の方法。
- 試料は、密閉パッケージを有することを特徴とする前記請求項のいずれか一つに記載の方法。
- パッケージのヘッドスペースを透過したまたはパッケージのヘッドスペースから反射された放射線が解析され、パッケージに含まれる気体量が定められることを特徴とする請求項13に記載の方法。
- 試料は、密閉されている間、分析されることを特徴とする前記請求項のいずれか一つに記載の方法。
- 試料は、100GHzから5THzの範囲の放射線で照射されることを特徴とする前記請求項のいずれか一つに記載の方法。
- 前記成分濃度に関する値を得るステップは、前記区画の導関数を得るステップを含むことを特徴とする前記請求項のいずれか一つに記載の方法。
- 前記導関数は、一次導関数であることを特徴とする請求項17に記載の方法。
- 前記導関数は、二次導関数であることを特徴とする請求項17に記載の方法。
- 前記成分濃度に関する値を得るステップは、前記検出放射線からバックグラウンド信号を差し引くステップを含むことを特徴とする前記請求項のいずれか一つに記載の方法。
- 前記バックグラウンド信号を差し引くステップは、前記試料の位置に設置された照合試料から反射されたまたは照合試料を透過した放射線を検出するステップを含むことを特徴とする請求項20に記載の方法。
- 前記バックグラウンド信号を差し引くステップは、スペクトルに直線フィッティングを行うステップと、前記スペクトルからその結果を差し引くステップとを含むことを特徴とする請求項20に記載の方法。
- 25GHzから100THzの範囲の複数の周波数を持つ放射線の利用であって、
密閉パッケージ内の気体量を定めるため、
25GHzから100THzの範囲の複数の周波数を持つ放射線で試料を照射するステップと、
前記試料の周波数領域波形を得るため、前記パッケージから反射されたおよび/または前記パッケージを透過した放射線を検出するステップと、
分子間励起または他の非分子内励起によるスペクトル特性を含む、前記周波数領域波形の少なくとも一つの関心区画を定めるステップと、
前記区画から前記パッケージ内の気体濃度に関する値を得るステップと、
が行われる、放射線の利用。 - 25GHzから100THzの範囲の複数の周波数を持つ放射線の利用であって、
薬剤の成分量を定めるため、
25GHzから100THzの範囲の複数の周波数を持つ放射線で試料を照射するステップと、
前記試料の周波数領域波形を得るため、前記薬剤から反射されたおよび/または前記試料を透過した放射線を検出するステップと、
分子間励起または他の非分子内励起によるスペクトル特性を含む、前記周波数領域波形の少なくとも一つの関心区画を定めるステップと、
前記区画から薬剤の成分濃度に関する値を得るステップと、
が行われる、放射線の利用。 - 放射線は、100GHzから5THzの範囲の複数の周波数を有することを特徴とする請求項23または24のいずれかに記載の放射線の利用。
- 試料を定量的に分析する装置であって、
25GHzから100THzの範囲の複数の周波数を持つ放射線で試料を照射する光源と、
前記試料の周波数領域波形を得るため、前記試料から反射されたおよび/または前記試料を透過した放射線を検出する検出器と、
分子間励起または他の非分子内励起によるスペクトル特性を含む、前記周波数領域波形の少なくとも一つの関心区画を定める手段と、
前記区画から試料の成分濃度に関する値を得る手段と、
を有する装置。 - 前記光源は、パルス放射線光源であることを特徴とする請求項26に記載の装置。
- 前記光源は、連続波放射線の光源であることを特徴とする請求項26に記載の装置。
- 前記光源は、光学的に非線形の素子を有し、該素子は、2または3以上の異なる周波数を持つ放射線での照射に応じて、所望の周波数範囲の放射線を出力するように構成されることを特徴とする請求項26乃至28のいずれか一つに記載の装置。
- 前記光源は、光伝導性アンテナを有し、該アンテナは、該アンテナに印加されるバイアスと、2または3以上の異なる周波数を持つ放射線での照射とに応じて、放射線を出力するように構成されることを特徴とする請求項26乃至28のいずれか一つに記載の装置。
- 前記光源は、100GHzから5THzの範囲の放射線を出力するように構成されることを特徴とする請求項26乃至30のいずれか一つに記載の装置。
- 前記検出器は、電気光学サンプリングを用いて、放射線を検出するように構成される
ことを特徴とする請求項26乃至30のいずれか一つに記載の装置。 - 前記検出器は、光伝導性アンテナを有することを特徴とする請求項26乃至30のいずれか一つに記載の装置。
- 実質的に、添付図面のいずれかを参照して示された方法。
- 実質的に、添付図面のいずれかを参照して示された装置。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0312627A GB2402471B (en) | 2003-06-02 | 2003-06-02 | An analysis method and apparatus |
PCT/GB2004/002225 WO2004106905A1 (en) | 2003-06-02 | 2004-05-24 | Method and apparatus for quantitative analysis using terahertz radiation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006526774A true JP2006526774A (ja) | 2006-11-24 |
Family
ID=9959171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006508373A Pending JP2006526774A (ja) | 2003-06-02 | 2004-05-24 | テラヘルツ放射線を用いた定量分析の方法および装置 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7663107B2 (ja) |
EP (1) | EP1634064A1 (ja) |
JP (1) | JP2006526774A (ja) |
GB (1) | GB2402471B (ja) |
WO (1) | WO2004106905A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008249525A (ja) * | 2007-03-30 | 2008-10-16 | Kansai Electric Power Co Inc:The | 碍子型避雷器の吸湿検出方法、碍子型避雷器の吸湿劣化検出方法、および碍子型避雷器の吸湿検出装置 |
EP2031375A2 (en) | 2007-08-31 | 2009-03-04 | Canon Kabushiki Kaisha | Inspection apparatus and inspection method using terahertz waves |
JP2009074807A (ja) * | 2007-09-18 | 2009-04-09 | Nippon Telegr & Teleph Corp <Ntt> | 無機塩の定性定量分析方法およびその分析装置 |
JP2009109282A (ja) * | 2007-10-29 | 2009-05-21 | Kao Corp | 赤外スペクトル測定装置および赤外スペクトル測定方法 |
JP2009162667A (ja) * | 2008-01-08 | 2009-07-23 | Sumco Techxiv株式会社 | 分光吸収測定方法及び分光吸収測定装置 |
EP2086074A2 (en) | 2008-01-29 | 2009-08-05 | Canon Kabushiki Kaisha | Pulse laser apparatus, terahertz measuring apparatus, and therahertz tomographic apparatus |
JP2010002214A (ja) * | 2008-06-18 | 2010-01-07 | Advantest Corp | 光検出装置 |
JP2013057696A (ja) * | 2012-12-28 | 2013-03-28 | Japan Atomic Energy Agency | テラヘルツ測定法 |
US8514399B2 (en) | 2008-02-05 | 2013-08-20 | Canon Kabushiki Kaisha | Compensation in terahertz time domain spectroscopy having two delays |
JP2016530538A (ja) * | 2013-09-12 | 2016-09-29 | ケストラル コーポレイションKestrel Corporation | 差分励起分光法 |
JP2017207282A (ja) * | 2016-05-16 | 2017-11-24 | 日本電信電話株式会社 | 成分濃度測定装置及び成分濃度測定方法 |
KR20180040636A (ko) | 2015-09-25 | 2018-04-20 | 가부시키가이샤 스크린 홀딩스 | 막두께 측정 장치 및 막두께 측정 방법 |
WO2021075344A1 (ja) * | 2019-10-18 | 2021-04-22 | フェムトディプロイメンツ株式会社 | 電磁波信号解析装置および電磁波信号解析用プログラム |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100416272C (zh) * | 2004-03-18 | 2008-09-03 | 广州白云山天心制药股份有限公司 | 测定头孢吡肟及其盐类原料与制剂中聚合物对照品溶液的制备方法 |
CA2567967C (en) | 2004-05-26 | 2016-08-02 | Picometrix, Llc | Terahertz imaging in reflection and transmission mode for luggage and personnel inspection |
JP4793753B2 (ja) * | 2006-01-31 | 2011-10-12 | 新潟県 | 分子間相互作用の解析装置 |
JP4898472B2 (ja) | 2006-04-11 | 2012-03-14 | キヤノン株式会社 | 検査装置 |
DE102006042642B4 (de) * | 2006-09-12 | 2010-06-24 | Batop Gmbh | Terahertz Time-Domain Spektrometer |
GB2465896B (en) * | 2007-01-29 | 2011-12-07 | Teraview Ltd | A pharmaceutical analysis method and apparatus |
JP2008185552A (ja) | 2007-01-31 | 2008-08-14 | Tohoku Univ | 測定装置および測定方法 |
US8010301B2 (en) * | 2008-03-28 | 2011-08-30 | The Boeing Company | Method and system for monitoring changes in a sample for a process or an environment |
US7835873B2 (en) * | 2008-03-28 | 2010-11-16 | The Boeing Company | Method and system for monitoring changes in a sample for a process or an environment |
KR100994247B1 (ko) * | 2008-08-20 | 2010-11-12 | 한국과학기술원 | 간섭 신호의 고조파 성분분석을 이용한 가속도계의 위상 감도 평가 방법 및 장치 |
AU2011216259B2 (en) * | 2010-02-12 | 2014-04-24 | Advanced Fusion Systems Llc | Method and system for detecting materials |
JP5455721B2 (ja) * | 2010-03-12 | 2014-03-26 | キヤノン株式会社 | テラヘルツ波測定装置及び測定方法 |
US9557223B2 (en) | 2010-07-23 | 2017-01-31 | The Regents Of The University Of Michigan | Mach-Zehnder interferometer having a doubly-corrugated spoofed surface plasmon polariton waveguide |
DE102010032382A1 (de) | 2010-07-27 | 2012-02-02 | Batop Gmbh | Fasergekoppeltes Terahertz Time-Domain Spektrometer |
JP2013012676A (ja) | 2011-06-30 | 2013-01-17 | Toshiba Corp | 磁気抵抗効果素子およびその製造方法 |
GB201210690D0 (en) * | 2012-06-15 | 2012-08-01 | Beers Centenary De Ag | Infra-red analysis of diamond |
US9341921B2 (en) | 2013-06-28 | 2016-05-17 | The Regents Of The University Of Michigan | Terahertz analog-to-digital converter employing active-controlled spoofed surface plasmon polariton architecture |
US9606054B2 (en) | 2013-09-30 | 2017-03-28 | Advantest Corporation | Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles |
US9417181B2 (en) | 2014-05-08 | 2016-08-16 | Advantest Corporation | Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control |
CN104266981A (zh) * | 2014-08-28 | 2015-01-07 | 北京环境特性研究所 | 一种太赫兹波吸收光谱识别方法 |
CN105566351A (zh) * | 2016-02-18 | 2016-05-11 | 海南灵康制药有限公司 | 一种采用粒子过程晶体产品分子组装与形态优化技术的头孢孟多酯钠新晶型化合物及制剂 |
CN107727608A (zh) * | 2017-11-17 | 2018-02-23 | 深圳市太赫兹***设备有限公司 | 吲哚美辛的检测方法 |
EP3492911A1 (de) * | 2017-11-29 | 2019-06-05 | Heraeus Quarzglas GmbH & Co. KG | Verfahren zur bestimmung der konzentration einer zusatzkomponente in einem körper aus keramischem oder glasigem werkstoff |
US11353396B2 (en) * | 2019-01-09 | 2022-06-07 | University Of Shanghai For Science And Technology | Method for qualitative and quantitative determination of key substances in mixture based on terahertz spectrum |
WO2022271079A1 (en) * | 2021-06-21 | 2022-12-29 | Anor Technologies Pte. Ltd. | Terahertz spectroscopy system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002055044A (ja) * | 2000-08-08 | 2002-02-20 | Toshiba Ceramics Co Ltd | 分光分析装置およびレーザラマン分光分析装置、これを用いた分光分析法 |
JP2002292832A (ja) * | 2001-03-30 | 2002-10-09 | Mitsubishi Heavy Ind Ltd | インキ膜厚・含水率計測装置及びこれを備える印刷機並びにインキ膜厚・含水率計測方法 |
WO2003069318A2 (en) * | 2002-02-15 | 2003-08-21 | Teraview Limited | An analysis apparatus and method |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6163382A (en) * | 1989-07-20 | 2000-12-19 | Netz; Yoel | Devices and methods for offset and similar printing systems |
US5939721A (en) * | 1996-11-06 | 1999-08-17 | Lucent Technologies Inc. | Systems and methods for processing and analyzing terahertz waveforms |
US6335625B1 (en) * | 1999-02-22 | 2002-01-01 | Paul Bryant | Programmable active microwave ultrafine resonance spectrometer (PAMURS) method and systems |
JP4368082B2 (ja) * | 1999-06-21 | 2009-11-18 | 浜松ホトニクス株式会社 | テラヘルツ波分光器 |
GB2359716B (en) * | 2000-02-28 | 2002-06-12 | Toshiba Res Europ Ltd | An imaging apparatus and method |
GB2372930B (en) * | 2000-03-03 | 2003-03-19 | Teraview Ltd | Apparatus and method for investigating a sample |
GB2360842B (en) * | 2000-03-31 | 2002-06-26 | Toshiba Res Europ Ltd | An apparatus and method for investigating a sample |
US6765212B2 (en) * | 2001-02-12 | 2004-07-20 | Analytical Spectral Devices, Inc. | System and method for combining reflectance data |
US6818450B2 (en) * | 2001-05-22 | 2004-11-16 | Monsanto Technology Llc | Use of infrared spectroscopy for on-line process control and endpoint detection |
US6819845B2 (en) * | 2001-08-02 | 2004-11-16 | Ultradots, Inc. | Optical devices with engineered nonlinear nanocomposite materials |
GB0122052D0 (en) * | 2001-09-12 | 2001-10-31 | Teraview Ltd | Imaging apparatus and method |
-
2003
- 2003-06-02 GB GB0312627A patent/GB2402471B/en not_active Expired - Fee Related
-
2004
- 2004-05-24 EP EP04734540A patent/EP1634064A1/en not_active Withdrawn
- 2004-05-24 WO PCT/GB2004/002225 patent/WO2004106905A1/en active Application Filing
- 2004-05-24 US US10/559,107 patent/US7663107B2/en not_active Expired - Lifetime
- 2004-05-24 JP JP2006508373A patent/JP2006526774A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002055044A (ja) * | 2000-08-08 | 2002-02-20 | Toshiba Ceramics Co Ltd | 分光分析装置およびレーザラマン分光分析装置、これを用いた分光分析法 |
JP2002292832A (ja) * | 2001-03-30 | 2002-10-09 | Mitsubishi Heavy Ind Ltd | インキ膜厚・含水率計測装置及びこれを備える印刷機並びにインキ膜厚・含水率計測方法 |
WO2003069318A2 (en) * | 2002-02-15 | 2003-08-21 | Teraview Limited | An analysis apparatus and method |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008249525A (ja) * | 2007-03-30 | 2008-10-16 | Kansai Electric Power Co Inc:The | 碍子型避雷器の吸湿検出方法、碍子型避雷器の吸湿劣化検出方法、および碍子型避雷器の吸湿検出装置 |
EP2031375A2 (en) | 2007-08-31 | 2009-03-04 | Canon Kabushiki Kaisha | Inspection apparatus and inspection method using terahertz waves |
US7963168B2 (en) | 2007-08-31 | 2011-06-21 | Canon Kabushiki Kaisha | Inspection apparatus and inspection method using electromagnetic wave |
JP2009074807A (ja) * | 2007-09-18 | 2009-04-09 | Nippon Telegr & Teleph Corp <Ntt> | 無機塩の定性定量分析方法およびその分析装置 |
JP2009109282A (ja) * | 2007-10-29 | 2009-05-21 | Kao Corp | 赤外スペクトル測定装置および赤外スペクトル測定方法 |
JP2009162667A (ja) * | 2008-01-08 | 2009-07-23 | Sumco Techxiv株式会社 | 分光吸収測定方法及び分光吸収測定装置 |
EP2086074A2 (en) | 2008-01-29 | 2009-08-05 | Canon Kabushiki Kaisha | Pulse laser apparatus, terahertz measuring apparatus, and therahertz tomographic apparatus |
US7953130B2 (en) | 2008-01-29 | 2011-05-31 | Canon Kabushiki Kaisha | Pulse laser apparatus, terahertz measuring apparatus, and terahertz tomographic apparatus |
US8179932B2 (en) | 2008-01-29 | 2012-05-15 | Canon Kabushiki Kaisha | Pulse laser apparatus, terahertz measuring apparatus, and terahertz tomographic apparatus |
US8514399B2 (en) | 2008-02-05 | 2013-08-20 | Canon Kabushiki Kaisha | Compensation in terahertz time domain spectroscopy having two delays |
JP2010002214A (ja) * | 2008-06-18 | 2010-01-07 | Advantest Corp | 光検出装置 |
JP2013057696A (ja) * | 2012-12-28 | 2013-03-28 | Japan Atomic Energy Agency | テラヘルツ測定法 |
JP2016530538A (ja) * | 2013-09-12 | 2016-09-29 | ケストラル コーポレイションKestrel Corporation | 差分励起分光法 |
KR20180040636A (ko) | 2015-09-25 | 2018-04-20 | 가부시키가이샤 스크린 홀딩스 | 막두께 측정 장치 및 막두께 측정 방법 |
JP2017207282A (ja) * | 2016-05-16 | 2017-11-24 | 日本電信電話株式会社 | 成分濃度測定装置及び成分濃度測定方法 |
WO2021075344A1 (ja) * | 2019-10-18 | 2021-04-22 | フェムトディプロイメンツ株式会社 | 電磁波信号解析装置および電磁波信号解析用プログラム |
JP2021067475A (ja) * | 2019-10-18 | 2021-04-30 | フェムトディプロイメンツ株式会社 | 電磁波信号解析装置および電磁波信号解析用プログラム |
KR20210154236A (ko) * | 2019-10-18 | 2021-12-20 | 펨토 디플로이멘츠 가부시키가이샤 | 전자파 신호 해석 장치 및 전자파 신호 해석용 프로그램 |
KR102565286B1 (ko) | 2019-10-18 | 2023-08-08 | 펨토 디플로이멘츠 가부시키가이샤 | 전자파 신호 해석 장치 및 전자파 신호 해석용 프로그램 |
JP7365042B2 (ja) | 2019-10-18 | 2023-10-19 | フェムトディプロイメンツ株式会社 | 電磁波信号解析装置および電磁波信号解析用プログラム |
Also Published As
Publication number | Publication date |
---|---|
GB2402471A (en) | 2004-12-08 |
GB2402471B (en) | 2006-01-18 |
EP1634064A1 (en) | 2006-03-15 |
WO2004106905A1 (en) | 2004-12-09 |
US7663107B2 (en) | 2010-02-16 |
US20060237650A1 (en) | 2006-10-26 |
GB0312627D0 (en) | 2003-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006526774A (ja) | テラヘルツ放射線を用いた定量分析の方法および装置 | |
US7244934B2 (en) | Analysis apparatus and method | |
US8378304B2 (en) | Continuous referencing for increasing measurement precision in time-domain spectroscopy | |
US8395777B2 (en) | Method and apparatus for trace gas detection using integrated wavelength modulated spectra across multiple lines | |
Pogány et al. | Towards traceability in CO2 line strength measurements by TDLAS at 2.7 µm | |
Moosmüller et al. | Cavity ring-down and cavity-enhanced detection techniques for the measurement of aerosol extinction | |
Weidmann et al. | Mid-infrared trace-gas sensing with a quasi-continuous-wave Peltier-cooled distributed feedback quantum cascade laser | |
JP7135608B2 (ja) | ガス吸収分光装置、及びガス吸収分光方法 | |
Mouret et al. | Versatile sub-THz spectrometer for trace gas analysis | |
Lambrecht et al. | Broadband spectroscopy with external cavity quantum cascade lasers beyond conventional absorption measurements | |
Nwaboh et al. | Tunable diode laser absorption spectroscopy sensor for calibration free humidity measurements in pure methane and low CO 2 natural gas | |
Nwaboh et al. | Measurement of CO amount fractions using a pulsed quantum-cascade laser operated in the intrapulse mode | |
Minutolo et al. | Self-and foreign-broadening and shift coefficients for C 2 H 2 lines at 1.54 μm | |
JP3352848B2 (ja) | 被験体内部性状測定装置校正用擬似対象物及び被験体内部性状測定装置の校正方法 | |
US20170052069A1 (en) | Method for determining the temperature of an infrared-active gas by means of infrared spectroscopy | |
Dunko et al. | Moisture assay of an antifungal by near-infrared diffuse reflectance spectroscopy | |
Ageev et al. | Remote detector of hazardous substances based on a tunable 13 С 16 О 2 laser | |
Chiarugi et al. | Diode laser-based gas analyser for the simultaneous measurement of CO 2 and HF in volcanic plumes | |
Kiselev et al. | Nonlinear absorption of femtosecond laser pulses (800 nm) by atmospheric air and water vapour | |
Parkes et al. | Absorption cross-sections and pressure broadening of rotational lines in the ν 5+ ν 9 band of ethene measured by diode laser cavity ring down spectroscopy | |
WO2021053804A1 (ja) | ガス吸収分光装置、及びガス吸収分光方法 | |
Edwards et al. | A tunable diode laser absorption spectrometer for moisture measurements in the low parts in 109 range | |
WO2021260752A1 (ja) | 遠赤外分光装置 | |
Yi et al. | High-accuracy and high-sensitivity spectroscopic measurement of dinitrogen pentoxide (N 2 O 5) in an atmospheric simulation chamber using a quantum cascade laser | |
Lucchesini et al. | Diode laser overtone spectroscopy of CO2 at 780 nm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100413 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100712 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100720 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100812 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100910 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100917 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101207 |